Combination immunotherapy improves survival in advanced liver cancer – Consumer Health News

MONDAY, Jan. 24, 2022 (HealthDay News) — STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as a first-line treatment for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 20-22 in San Francisco.

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Comprehensive Cancer Center in New York City, and colleagues randomly assigned 1,171 patients with stage III or IV CuCHC and no prior systemic therapy with tremelimumab plus durvalumab (STRIDE) , durvalumab alone (D), or sorafenib (S).

The researchers reported that overall survival (OS) was significantly improved for STRIDE compared to S (relative risk, 0.78; 96% confidence interval, 0.65 to 0.92; P=0.0035). Non-inferiority of OS was satisfied for D compared to S (relative risk, 0.86; 96% confidence interval, 0.73 to 1.03). Median progression-free survival did not differ between the groups. Objective response rates were higher for STRIDE (20.1%) and D (17.0%) than for S (5.1%). No new safety signal was observed. Grade 3/4 treatment-related adverse events (TRAE) occurred in 25.8% for STRIDE, 12.9% for D, and 36.9% for S. Discontinuation due to TRAE occurred in 8.2% for STRIDE, 4.1% for D and 11.0% for S

“We plan to drill down further on the results based on the causes of the disease, such as viral infection, as well as the regions of the liver affected,” Abou-Alfa said in a statement.

The study was funded by AstraZeneca, the maker of durvalumab.

Press release

More information

Comments are closed.